Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


Abdul-Jawad S. et al. Mol Ther (2016) Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.

Ahmed T. et al. Vaccine. (2016) Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes.

Alagaratnam J. et al. HIV Med. (2019) No evidence of neuroaxonal injury following latency reactivating with vorinostat and HIV-specific vaccination: a randomised controlled study.

Borthwick N. et al. PLoS One. (2017) Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines.

Borthwick Net al. PLoS One. (2017) Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines.

Borthwick Net al. Vaccines. (2019) Novel nested peptide epitopes recognized by CD4+ T cells induced by HIV-1 conserved-region vaccines.

Borthwick NJ. et al. PLoS One. (2018) Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.

Broset E. et al. Mol Ther Methods Clin Dev. (2019) MTBVAC based TB-HIV vaccine is safe, elicits HIV-T cell responses and protects against Mycobacterium tuberculosis in mice.

Fidler S. et al. Lancet. (2019) A randomized comparison of antiretroviral therapy alone versus antiretroviral therapy with a ‘kick-and-kill’ approach, on measures of the HIV reservoir amongst participants with recent HIV infection: the RIVER trial.

Hancock G. et al. J Int AIDS Soc. (2017) Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.

Hanke T. Expert Review of Vacc. (2019) Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials.

Hannoun Z. et al. Immunol Lett. (2018) Identification of novel HIV-1-derived HLA-E-binding peptides.

Hartnell F. et al. Front Immunol. (2019) A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.

Kilpeläinen A. et al. Frontiers Immunol. (2019) Priming with recombinant BCG expressing novel HIV-1 mosaic immunogens and boosting with recombinant ChAdOx1 is safe, stable and elicits HIV-1-specific T-cell responses in the BALB/c mice.

Kilpeläinen A. et al. Vaccines. (2019) Recombinant BCG expressing HTI prime and recombinant ChAdOx1 boost is safe and elicits HIV-1-specific T-cell responses in BALB/c mice.

Mothe B. et al. Lancet eClinMed. (2019) Therapeutic vaccination refocuses T-cell Responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study).

Moyo N. et al. PLoS One. (2017) Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens.

Moyo N. et al. Mol Ther Methods Clin Dev. (2018) Efficient Induction of T Cells against Conserved HIV – 1 Regions by Mosaic vaccines Delivered as Self-Amplifying mRNA.

Murakoshi H. et al Retrovirology. (2018) CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication.

Mutua G. et al. Mol ther Methods Clin Dev. (2016) Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults.

Ondondo B. et al. Vaccine. (2013) Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.

Rahim M.N. et al. PLoS Pathog. (2019) Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine.

Thornhill J. et al. HIV Med. (2019) The impact of vorinostat and therapeutic vaccine on gut HIV DNA: the RIVER gut study.

Wee E.G. et al. Mol Ther Methods Clin Dev. (2019) Parallel induction of CH505 B-cell ontogeny-guided neutralizing antibodies and tHIVconsvX conserved mosaic-specific T cells against HIV. 

Zou C. et al. J Virol. (2019) Effective Suppression of HIV – 1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.

HIV Prevalence and Incidence

Kamali A. et al. PLoS One (2015) Creating an African HIV clinical research and prevention trials network: HIV prevalence, incidence and transmission.

Sanders EJ. et al. AIDS (2017Differences in acute retroviral syndrome by HIV-1 subtype in a multicentre cohort study in Africa.

Featured Articles

Conference & Meeting Presentations 

The 9th EDCTP Forum, Lisbon, Portugal (Sep 2018) Hanke T. – T-cell Vaccine Strategy_Presentation (PDF)

HVTN Full Group Meeting, Washington D.C., USA (May 2019) Hanke T. – Conserved Mosaic Vaccines for Induction of Effective T-cell Responses (PDF)

Official Opening of the KAVI-ICR Building Extension, Nairobi, Kenya (July 2019) Hanke T. – The T-Cell Vaccine Strategy_Presentation (PDF)

Devo Meeting (Nov 2019) GREAT Project Team – The GREAT Project (PDF)